Santa Cruz de Tenerife, 9 de junio de 2025.
Molefy Pharma, a biotech company born from the collaboration between ARQUIMEA and CSIC, has announced the launch of its new corporate website www.molefypharma.com , a platform designed to offer comprehensive insight into the company’s mission, scientific research, and advancements in the development of innovative treatments for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases.
Founded in 2024, Molefy Pharma is committed to changing the course of ALS through a science-first, patient-centered approach. With a clear vision — ALS can’t wait, and neither can we — the company is pioneering a new generation of treatments aimed at not just slowing disease progression, but potentially reversing its devastating effects.
A Platform for progress
The website provides detailed information about Molefy’s scientific approach, particularly its lead candidate AP-2, a small molecule targeting TDP-43 proteinopathy, a core pathological feature of ALS. AP-2 has shown promising preclinical results, with efficacy in restoring cellular homeostasis and a strong pharmacological safety profile.
Visitors can also explore the Insights section, which highlights the company’s latest scientific publications, research milestones, and news updates. This resource aims to keep the scientific and medical communities informed on Molefy Pharma’s journey from preclinical discovery to clinical application.
Building the future of ALS treatment
ALS remains one of the most challenging and under-addressed neurodegenerative diseases. Despite decades of research, no current therapies have been approved to halt or reverse its progression. Molefy Pharma is determined to change that reality by addressing the molecular drivers of the disease with precision, innovation, and urgency.
With a highly skilled team, Molefy Pharma is well-positioned to advance toward Phase I clinical trials by the end of the year and bring its molecule closer to market.
About Molefy Pharma
Founded in 2024, Molefy Pharma is a biotechnology company focused on the development of transformative treatments for neurodegenerative diseases, with an initial emphasis on ALS. Combining scientific excellence, strategic collaboration, and cutting-edge technologies, it is committed to accelerating the discovery of real solutions for patients who need them most.
About ARQUIMEA
ARQUIMEA is a Spanish technology company operating globally, providing innovative solutions and products in highly demanding sectors such as Aerospace, Defense & Security, Science Industry, and Fintech. With a strong commitment to research and development, ARQUIMEA fosters cutting-edge innovation through strategic collaborations.